PL438742A1 - Liposom kationowy wiążący i stabilizujący RNA, jego zastosowanie i sposób ładowania liposomu emetyną - Google Patents

Liposom kationowy wiążący i stabilizujący RNA, jego zastosowanie i sposób ładowania liposomu emetyną

Info

Publication number
PL438742A1
PL438742A1 PL438742A PL43874221A PL438742A1 PL 438742 A1 PL438742 A1 PL 438742A1 PL 438742 A PL438742 A PL 438742A PL 43874221 A PL43874221 A PL 43874221A PL 438742 A1 PL438742 A1 PL 438742A1
Authority
PL
Poland
Prior art keywords
liposome
emetine
loading
weight
cationic
Prior art date
Application number
PL438742A
Other languages
English (en)
Other versions
PL249473B1 (pl
Inventor
Olga Święch
Original Assignee
Bs Biotechna Spółka Z Ograniczoną Odpowiedzialnością
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bs Biotechna Spółka Z Ograniczoną Odpowiedzialnością filed Critical Bs Biotechna Spółka Z Ograniczoną Odpowiedzialnością
Priority to PL438742A priority Critical patent/PL249473B1/pl
Priority to EP22797521.6A priority patent/EP4398883A1/en
Priority to CA3229288A priority patent/CA3229288A1/en
Priority to PCT/PL2022/000046 priority patent/WO2023022615A1/en
Priority to IL310853A priority patent/IL310853A/en
Priority to CN202280069568.1A priority patent/CN118139613A/zh
Priority to JP2024533925A priority patent/JP2024531829A/ja
Priority to US18/683,763 priority patent/US20240382425A1/en
Publication of PL438742A1 publication Critical patent/PL438742A1/pl
Publication of PL249473B1 publication Critical patent/PL249473B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/51—Physical structure in polymeric form, e.g. multimers, concatemers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Manufacturing & Machinery (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Przedmiotem zgłoszenia jest liposom kationowy wiążący i stabilizujący RNA, charakteryzujący się tym, że składa się z lipidów obojętnych w ilości od 12,4 do 49% wagowych, lipidów kationowych w ilości od 16,2 do 55% wagowych, lipidów modyfikowanych glikolem polietylenowym w ilości 12,9 do 15,1% wagowych i cholesterolu w ilości od 15,4 do 18,1% wagowych i charakteryzuje się wielkością od 80 nm do 190 nm, współczynnikiem polidyspersji od 0,06 do 0,23 oraz potencjałem zeta + 19 mV do + 55 mV, przy czym jest załadowny RNA. Przedmiotem zgłoszenia jest także zastosowanie ww. liposomu i sposób ładowania liposomu emetyną.
PL438742A 2021-08-14 2021-08-14 Liposom kationowy wiążący i stabilizujący RNA, jego zastosowanie jako nośnika leku oraz w terapii genowej i sposób ładowania liposomu emetyną PL249473B1 (pl)

Priority Applications (8)

Application Number Priority Date Filing Date Title
PL438742A PL249473B1 (pl) 2021-08-14 2021-08-14 Liposom kationowy wiążący i stabilizujący RNA, jego zastosowanie jako nośnika leku oraz w terapii genowej i sposób ładowania liposomu emetyną
EP22797521.6A EP4398883A1 (en) 2021-08-14 2022-08-15 Rna binding and stabilising cationic liposome, its application and method of loading the liposome with emetine
CA3229288A CA3229288A1 (en) 2021-08-14 2022-08-15 Rna binding and stabilising cationic liposome, its application and method of loading the liposome with emetine
PCT/PL2022/000046 WO2023022615A1 (en) 2021-08-14 2022-08-15 Rna binding and stabilising cationic liposome, its application and method of loading the liposome with emetine
IL310853A IL310853A (en) 2021-08-14 2022-08-15 A cationic liposome binds and stabilizes RNA, its application and method for loading the liposome with EMETINE
CN202280069568.1A CN118139613A (zh) 2021-08-14 2022-08-15 结合并稳定rna的阳离子脂质体、其应用以及依米丁负载于脂质体的方法
JP2024533925A JP2024531829A (ja) 2021-08-14 2022-08-15 Ｒｎａに結合して安定化させるカチオン性リポソーム、その応用及びリポソームにエメチンを充填する方法
US18/683,763 US20240382425A1 (en) 2021-08-14 2022-08-15 RNA binding and stabilising cationic liposome, its application and method of loading the liposome with emetine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL438742A PL249473B1 (pl) 2021-08-14 2021-08-14 Liposom kationowy wiążący i stabilizujący RNA, jego zastosowanie jako nośnika leku oraz w terapii genowej i sposób ładowania liposomu emetyną

Publications (2)

Publication Number Publication Date
PL438742A1 true PL438742A1 (pl) 2023-02-20
PL249473B1 PL249473B1 (pl) 2026-04-27

Family

ID=84043894

Family Applications (1)

Application Number Title Priority Date Filing Date
PL438742A PL249473B1 (pl) 2021-08-14 2021-08-14 Liposom kationowy wiążący i stabilizujący RNA, jego zastosowanie jako nośnika leku oraz w terapii genowej i sposób ładowania liposomu emetyną

Country Status (8)

Country Link
US (1) US20240382425A1 (pl)
EP (1) EP4398883A1 (pl)
JP (1) JP2024531829A (pl)
CN (1) CN118139613A (pl)
CA (1) CA3229288A1 (pl)
IL (1) IL310853A (pl)
PL (1) PL249473B1 (pl)
WO (1) WO2023022615A1 (pl)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL444722A1 (pl) * 2023-05-03 2024-11-04 Bs Biotechna Spółka Z Ograniczoną Odpowiedzialnością Modyfikowany liposom do przenoszenia leków, zastosowanie liposomu do przenoszenia leków, zwłaszcza o działaniu antynowotworowym oraz sposoby ładowania liposomu lekami, zwłaszcza o działaniu antynowotworowym
PL444723A1 (pl) * 2023-05-03 2024-11-04 Bs Biotechna Spółka Z Ograniczoną Odpowiedzialnością Kompozycja farmaceutyczna, stosowana w zapobieganiu lub leczeniu chorób nowotworowych i chorób wynikających z nadmiernej proliferacji komórek oraz liposom zawierający tę kompozycję

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025258702A1 (ja) * 2024-06-13 2025-12-18 国立大学法人徳島大学 薬物送達ビヒクル

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070293449A1 (en) * 2006-06-20 2007-12-20 Nastech Pharmaceutical Company Inc. Compositions and methods for delivery of double-stranded rna
JP2016529284A (ja) * 2013-08-27 2016-09-23 ノースイースタン ユニバーシティ ナノ粒子薬物デリバリシステムおよび、癌および神経外傷の治療方法
CN114642735A (zh) * 2015-01-21 2022-06-21 菲泽尔克斯公司 用于将治疗剂和诊断剂递送到细胞中的方法、组合物和系统
AU2016291228B2 (en) * 2015-07-09 2020-04-09 Insmed Incorporated Compositions and methods for treating lung diseases and lung injury

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL444722A1 (pl) * 2023-05-03 2024-11-04 Bs Biotechna Spółka Z Ograniczoną Odpowiedzialnością Modyfikowany liposom do przenoszenia leków, zastosowanie liposomu do przenoszenia leków, zwłaszcza o działaniu antynowotworowym oraz sposoby ładowania liposomu lekami, zwłaszcza o działaniu antynowotworowym
PL444723A1 (pl) * 2023-05-03 2024-11-04 Bs Biotechna Spółka Z Ograniczoną Odpowiedzialnością Kompozycja farmaceutyczna, stosowana w zapobieganiu lub leczeniu chorób nowotworowych i chorób wynikających z nadmiernej proliferacji komórek oraz liposom zawierający tę kompozycję
PL247852B1 (pl) * 2023-05-03 2025-09-08 Bs Biotechna Spolka Z Ograniczona Odpowiedzialnoscia Kompozycja farmaceutyczna, stosowana w zapobieganiu lub leczeniu chorób nowotworowych i chorób wynikających z nadmiernej proliferacji komórek oraz liposom zawierający tę kompozycję
PL249575B1 (pl) * 2023-05-03 2026-05-11 Bs Biotechna Spółka Z Ograniczoną Odpowiedzialnością Modyfikowany liposom do przenoszenia leków, zwłaszcza o działaniu antynowotworowym

Also Published As

Publication number Publication date
WO2023022615A1 (en) 2023-02-23
IL310853A (en) 2024-04-01
JP2024531829A (ja) 2024-08-29
PL249473B1 (pl) 2026-04-27
CA3229288A1 (en) 2023-02-23
EP4398883A1 (en) 2024-07-17
US20240382425A1 (en) 2024-11-21
CN118139613A (zh) 2024-06-04

Similar Documents

Publication Publication Date Title
Bollerslev et al. Risk and return: Long-run relations, fractional cointegration, and return predictability
Deng et al. Plasma protein binding of positively and negatively charged polymer-coated gold nanoparticles elicits different biological responses
JOP20200102B1 (ar) جزيئات ترابط إنتجرين واستخداماتها
WO2013120829A3 (de) Stabile wasser in öl emulsionen mit spreitfähigen ölen
SA520420729B1 (ar) الأحماض النووية الريبوزية الدليلية المُعدلة لتصحيح الجين
EP3914259A4 (en) RNA-EDITING OLIGONUCLEOTIDES AND THEIR USE
EP3787996A4 (en) NANOPARTICLES FOR GENE EXPRESSION AND THEIR USES
MX2020003339A (es) Arn guía de cpf1 modificado.
Austin et al. The billion dollar startup club
Heal Topological social choice
Brauneder The" First" European Codification of Private Law: The ABGB
EP3974418C0 (en) CRYSTALLINE FORM OF 1,4-[BIS(1,2-BENZISOSELENAZOL-3(2H)-ONE)]BUTANE, ITS PREPARATION PROCESS AND ITS USE
Hiraguchi et al. Taxing capital is a good idea: The role of idiosyncratic risk in an OLG model
Pike Endogeneity in social influence and transportation mode choice using ego-networks
PL438912A1 (pl) Topogami i sposób tworzenia splecionych jednoniciowych pierścieni DNA
Yoon Wh-island Effects of Wh-in-situ Questions in Korean
Geline Rationality of finite group representations and local subgroups
Nilforoshan et al. The need for collective security in the Persian Gulf region Looking at the relations between the Islamic Republic of Iran and Saudi Arabia.
Long et al. The Role of Upper-crustal Thickening in Spatially-focusing Synorogenic Extension: A Case Study from the Late Cretaceous-Paleocene Nevadaplano
Naveed et al. Physical engineering of rhizosphere by plant exudates varies with species, origin and microbial decomposition
Bāqery Journal of Voice of Women: a Review
Tetsuya et al. Correction to: Are cognitive, affective, and Eudaimonic dimensions of subjective well-being differently related to consumption? evidence from Japan
Melnyk et al. To think or not to think: The effect of cognitive deliberation on social norm influence
Fallah Tafti Figh principles and rules based on the rationality and unity of Muslims in modern Islamic civilization
Hong Inter-Korean Summit, North Korea-US Summit, and Road Map to Peace on the Korean Peninsula: Crafting New Road Map based on Package Settlement· Synchronous Implementation